Search results for Wuxi Biologics

WuXi AppTec posts record first-quarter revenue on strong global demand

China’s drug maker WuXi AppTec reported record first-quarter revenue, as a robust order backlog and sustained demand from global pharmaceutical companies supported growth. For the...

WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index

SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognit...

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Devel...

Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clientsZero non-conformities dem...

How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients

In a complex therapeutic landscape, WuXi AppTec is simplifying the path from discovery to patient. Find out how.

WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index

SHANGHAI, May 17, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for th...

Akari locks arms with WuXi XDC to develop and manufacture novel ADC treatment

Oncology biotech Akari Therapeutics has announced a partnership with WuXi XDC, an antibody-drug conjugate (ADC) development and manufacturing company, to accelerate Akari’s drug de...

Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time

SHANGHAI, April 20, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned...

Rethinking the path to IND: How an integrated, global approach can accelerate biologics development

Thermo Fisher’s future US-based option for biologic and sterile fill-finish manufacturing will help to alleviate capacity bottlenecks globally.

Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing

The project leverages AGC Biologics’ global network, having completed cell line development in Copenhagen, Denmark, to be followed by tech transfer to Chiba, Japan, for the next ma...

<![CDATA[Haisco Enters $745 Million Exclusive License Agreement with AbbVie ]]>

WACKER offers Contract Research Services (CRS) for nucleic acid-based pharmaceuticals

- - • The new CRS expand WACKER's offering for biotech and biopharmaceutical customers worldwide and complement Wacker Biotech's CDMO services. - - • The Munich team at the...

RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing So...

Partnership Delivers RoosterBio's Research-Grade and CliniControlâ„¢ cGMP Media Platforms to China's Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Imm...

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biop...

<![CDATA[GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China ]]&...

Beigene

Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

<![CDATA[Amgen’s Tarlatamab Approved in China ]]>

Smile Please: Wisconsin Welcomes FUJIFILM Cellular Dynamics New Headquarters

CEO Tomoyuki Hasegawa discusses the vast potential of stem cells and the company’s life sciences goals. The post Smile Please: Wisconsin Welcomes FUJIFILM Cellular Dynamics New Hea...

Light-Controlled Gene Expression Platform Reportedly Doubles Standard Fed-Batch Manufacturing Performance

The real opportunity lies in next generation complex biologics such as multispecifics, cytokines, and fusion proteins. These molecules represent more than 50% of today's early pipe...

<![CDATA[Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement]]>

LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma

SEOUL, South Korea, May 17, 2026 /PRNewswire/ -- LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative...

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical...

BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui

BeOne Medicines is paying $20 million upfront to reserve the right to buy a preclinical PD-1xCTLA-4xVEGF trispecific antibody from China’s Huahui Health.

<![CDATA[What Does it Take to Scale Cell and Gene Therapies from Discovery to Commercialization]]>